Anthrax post-vaccinal cell-mediated immunity in humans: kinetics pattern. 1997

E Shlyakhov, and E Rubinstein, and I Novikov
Infectious Diseases Unit, Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, Israel.

Seven groups (2596 subjects) were vaccinated with a human live anthrax vaccine (HLAV) by three different routes (scarification, subcutaneous and aerosol). The vaccinees were tested for anthrax cell-mediated immunity using the "Anthraxin" skin test at 7, 15, 30, 90, 180 and 365 days following vaccination. The kinetic pattern obtained from all groups, shows a significant, five-phased curve: phase I (2-6 days post-vaccination) shows a slow increase in positive Anthraxin skin reactions. Phase II (7-15 days post-vaccination) shows an exponential rise to a maximum at day 15. Phase III (16-30 days post-vaccination) shows a decrease to day 30. Phase IV (31-90 days post-vaccination) leads to a relative restoration of the positive skin reactions. During phase V (91-365 days post-vaccination) there is a continuous decrease in positive Anthraxin skin reactions. The loss of the skin test reaction on day 30 is a characteristic feature of post vaccination anthrax cell-mediated immunity. It may be due to a blockade of macrophages by lethal anthrax toxin released by the multiplying vaccine strain. Epidemiological observations of HLAV protective rates correlate with the phases of the skin reaction kinetics.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000942 Antigens, Bacterial Substances elaborated by bacteria that have antigenic activity. Bacterial Antigen,Bacterial Antigens,Antigen, Bacterial
D001408 Bacillus anthracis A species of bacteria that causes ANTHRAX in humans and animals.

Related Publications

E Shlyakhov, and E Rubinstein, and I Novikov
January 2002, Journal of immunology (Baltimore, Md. : 1950),
E Shlyakhov, and E Rubinstein, and I Novikov
August 1984, Indian pediatrics,
E Shlyakhov, and E Rubinstein, and I Novikov
August 1976, Veterinariia,
E Shlyakhov, and E Rubinstein, and I Novikov
October 1985, Klinische Wochenschrift,
E Shlyakhov, and E Rubinstein, and I Novikov
January 1948, Bulletin of the World Health Organization,
E Shlyakhov, and E Rubinstein, and I Novikov
September 1960, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
E Shlyakhov, and E Rubinstein, and I Novikov
February 1971, Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles,
E Shlyakhov, and E Rubinstein, and I Novikov
January 1964, Voprosy virusologii,
E Shlyakhov, and E Rubinstein, and I Novikov
March 1931, Canadian Medical Association journal,
Copied contents to your clipboard!